The Moderna Pullback is Worth a Shot

A little over two years ago Moderna (NASDAQ:MRNA) was a relative unknown in the world of investing. The Massachusetts-based biotech company was making its public market debut hoping investors would take to its novel approach to drug and vaccine development. My how times have changed.

Leave a Reply

Your email address will not be published. Required fields are marked *